|
SI1147087T1
(en)
*
|
1999-01-15 |
2005-10-31 |
Altana Pharma Ag |
Phenanthridine-n-oxides with pde-iv inhibiting activity
|
|
ATE294793T1
(de)
|
1999-01-15 |
2005-05-15 |
Altana Pharma Ag |
Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
|
|
EP1212089B1
(de)
|
1999-08-21 |
2006-03-22 |
ALTANA Pharma AG |
Synergistische kombination von roflumilast und salmeterol
|
|
US6953774B2
(en)
|
2000-08-11 |
2005-10-11 |
Applied Research Systems Ars Holding N.V. |
Methods of inducing ovulation
|
|
ATE305467T1
(de)
|
2001-01-31 |
2005-10-15 |
Pfizer Prod Inc |
Als inhibitoren von pde4-isozymen geeignete etherderivate
|
|
US7250518B2
(en)
|
2001-01-31 |
2007-07-31 |
Pfizer Inc. |
Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
|
|
WO2002060898A1
(en)
|
2001-01-31 |
2002-08-08 |
Pfizer Products Inc. |
Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
|
|
IL156413A0
(en)
|
2001-01-31 |
2004-01-04 |
Pfizer Prod Inc |
Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
|
|
ES2427930T3
(es)
*
|
2001-05-23 |
2013-11-04 |
Mitsubishi Tanabe Pharma Corporation |
Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
|
|
CN1604776A
(zh)
|
2001-10-16 |
2005-04-06 |
记忆药物公司 |
作为用于治疗神经病综合症的pde-4抑制剂的4-(4-烷氧基-3-羟基苯基)-2-吡咯烷酮衍生物
|
|
AR037517A1
(es)
*
|
2001-11-05 |
2004-11-17 |
Novartis Ag |
Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
|
|
PT1463493E
(pt)
|
2001-12-14 |
2008-01-04 |
Serono Lab |
Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
|
|
AU2003295656B2
(en)
|
2002-11-19 |
2010-11-11 |
Memory Pharmaceuticals Corporation |
Pyridine N-oxide compounds as phosphodiesterase 4 inhibitors
|
|
GB0229281D0
(en)
*
|
2002-12-16 |
2003-01-22 |
Novartis Ag |
Organic compounds
|
|
MXPA05010373A
(es)
|
2003-04-01 |
2005-12-05 |
Applied Research Systems |
Inhibidores de fosfodiesterasas en infertilidad.
|
|
EP1613590A2
(de)
*
|
2003-04-16 |
2006-01-11 |
Memory Pharmaceutical Corporation |
4-(3,4-disubstituiertes phenyl)-pyrrolidin-2-on-verbindungen als phosphodiesterase 4 inhibitoren
|
|
AU2004232973A1
(en)
*
|
2003-04-18 |
2004-11-04 |
Memory Pharmaceuticals Corporation |
Pyrazole derivatives as phosphodiesterase 4 inhibitors
|
|
TW200519106A
(en)
|
2003-05-02 |
2005-06-16 |
Novartis Ag |
Organic compounds
|
|
MY141255A
(en)
|
2003-12-11 |
2010-03-31 |
Memory Pharm Corp |
Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
WO2006073413A1
(en)
*
|
2004-02-20 |
2006-07-13 |
The Board Of Trustees Of The University Of Illinois |
Blood pressure reduction in salt-sensitive
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
WO2006002284A1
(en)
*
|
2004-06-22 |
2006-01-05 |
Rigel Pharmaceuticals, Inc. |
Ubiquitin ligase inhibitors
|
|
CA2577171A1
(en)
*
|
2004-09-14 |
2006-03-23 |
Novartis Ag |
Process for the preparation of 6, 8-substituted `1, 7 naphthpyridin derivatives by reacting the 8-halo-`1, 7 naphthpyridin-derivate with an organic boronic acid derivatives and intermadiates of this process
|
|
CA2584317A1
(en)
*
|
2004-10-15 |
2006-04-27 |
Memory Pharmaceuticals Corporation |
Pyrazole derivatives as phosphodiesterase 4 inhibitors
|
|
EP1802615A1
(de)
*
|
2004-10-20 |
2007-07-04 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase-4-inhibitoren
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
JP2006241111A
(ja)
*
|
2005-03-04 |
2006-09-14 |
Univ Nihon |
新規ベンゾフロキサン及びその合成法
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
EP2258358A3
(de)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenese mit Acetylcholinesterasehemmer
|
|
EP1928437A2
(de)
|
2005-08-26 |
2008-06-11 |
Braincells, Inc. |
Neurogenese mittels muscarinrezeptormodulation
|
|
EP1940389A2
(de)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation von neurogenese durch pde-hemmung
|
|
KR20080064173A
(ko)
*
|
2005-10-21 |
2008-07-08 |
글락소 그룹 리미티드 |
항균제로서 유용한 페리 축합 트리시클릭 화합물
|
|
RU2421464C2
(ru)
|
2005-10-21 |
2011-06-20 |
Новартис Аг |
Человеческие антитела к il-13 и их терапевтическое применение
|
|
US20070112017A1
(en)
|
2005-10-31 |
2007-05-17 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
|
ATE465163T1
(de)
|
2005-12-22 |
2010-05-15 |
Glaxo Group Ltd |
Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
|
|
GB0601951D0
(en)
*
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2322525B1
(de)
|
2006-04-21 |
2013-09-18 |
Novartis AG |
Purinderivate als Adenosin A2A Rezeptoragonisten
|
|
WO2007134077A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
AU2007249399A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
EP2068872A1
(de)
|
2006-09-08 |
2009-06-17 |
Braincells, Inc. |
Kombinationen mit einem 4-acylaminopyridin-derivat
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
WO2008037477A1
(en)
|
2006-09-29 |
2008-04-03 |
Novartis Ag |
Pyrazolopyrimidines as p13k lipid kinase inhibitors
|
|
CN101522682A
(zh)
|
2006-10-30 |
2009-09-02 |
诺瓦提斯公司 |
作为抗炎剂的杂环化合物
|
|
PL2104535T3
(pl)
|
2007-01-10 |
2011-05-31 |
Irm Llc |
Związki i kompozycje jako inhibitory proteazy aktywujące kanały
|
|
DE602008005140D1
(de)
|
2007-05-07 |
2011-04-07 |
Novartis Ag |
Organische verbindungen
|
|
MX2010006421A
(es)
|
2007-12-10 |
2010-06-25 |
Novartis Ag |
Compuestos organicos.
|
|
MX2010007604A
(es)
|
2008-01-11 |
2010-08-02 |
Novartis Ag |
Pirimidinas como inhibidores de cinasa.
|
|
US8268834B2
(en)
|
2008-03-19 |
2012-09-18 |
Novartis Ag |
Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
|
|
JP2011522860A
(ja)
|
2008-06-10 |
2011-08-04 |
ノバルティス アーゲー |
上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
|
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
JP5781510B2
(ja)
|
2009-08-12 |
2015-09-24 |
ノバルティス アーゲー |
ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
|
|
PE20121148A1
(es)
|
2009-08-17 |
2012-09-07 |
Intellikine Llc |
Compuestos heterociclicos y usos de los mismos
|
|
JP5775871B2
(ja)
|
2009-08-20 |
2015-09-09 |
ノバルティス アーゲー |
ヘテロ環式オキシム化合物
|
|
MX2012004792A
(es)
|
2009-10-22 |
2013-02-01 |
Vertex Pharma |
Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
EP2593452B1
(de)
|
2010-07-14 |
2017-01-18 |
Novartis AG |
Heterocyclische verbindungen als ip-rezeptoragonisten
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
|
WO2012116217A1
(en)
|
2011-02-25 |
2012-08-30 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
US9056867B2
(en)
|
2011-09-16 |
2015-06-16 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
CA2856803A1
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
WO2013106547A1
(en)
|
2012-01-10 |
2013-07-18 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
AR089698A1
(es)
|
2012-01-13 |
2014-09-10 |
Novartis Ag |
Compuestos heterociclicos antagonistas del receptor ip
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
JP2015512425A
(ja)
|
2012-04-03 |
2015-04-27 |
ノバルティス アーゲー |
チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
|
|
JP5907006B2
(ja)
*
|
2012-09-04 |
2016-04-20 |
エヌ・イーケムキャット株式会社 |
ビフェニル化合物の合成方法
|
|
JP5907005B2
(ja)
*
|
2012-09-04 |
2016-04-20 |
エヌ・イーケムキャット株式会社 |
ビフェニル化合物の合成方法
|
|
ES2637719T3
(es)
|
2013-02-13 |
2017-10-16 |
Novartis Ag |
Compuestos heterocíclicos agonistas del receptor IP
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
EP2968340A4
(de)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Kombination von kinaseinhibitoren und verwendungen davon
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
KR20160141856A
(ko)
|
2014-04-24 |
2016-12-09 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
|
|
EP3134397A1
(de)
|
2014-04-24 |
2017-03-01 |
Novartis AG |
Aminopyrazinderivate als phosphatidylinositol-3-kinasehemmer
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
US9741941B2
(en)
|
2014-04-29 |
2017-08-22 |
Universal Display Corporation |
Organic electroluminescent materials and devices
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
ES2831416T3
(es)
|
2014-07-31 |
2021-06-08 |
Novartis Ag |
Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
|
|
WO2020250116A1
(en)
|
2019-06-10 |
2020-12-17 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
|
|
PE20220346A1
(es)
|
2019-08-28 |
2022-03-14 |
Novartis Ag |
Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|